DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Tirrell"


12 mentions found


☆ Appeals court dismisses Johnson and Johnson talc bankruptcy case
  + stars: | 2023-01-30 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAppeals court dismisses Johnson and Johnson talc bankruptcy caseCNBC's Meg Tirrell joins 'Halftime Report' to report on the U.S. appeals court decision to toss out Johnson and Johnson's talc powder settlements in to a bankruptcy case, the reasons behind the ruling, and the next steps for J&J.
☆ Moderna's phase three RSV trial found to be 83.7% effective in older adults
  + stars: | 2023-01-17 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna's phase three RSV trial found to be 83.7% effective in older adultsCNBC's Meg Tirrell joins 'Closing Bell' to discuss Moderna's phase three trial results for its RSV vaccine, the decision to submit the vaccine for regulatory review and the competitive landscape for RSV vaccines.
☆ Regeneron CEO on the prospects for its eye drug Eylea
  + stars: | 2023-01-10 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRegeneron CEO on the prospects for its eye drug EyleaCNBC's Meg Tirrell sits down with Regeneron CEO Len Schleifer to discuss the company's future, next-gen COVID antibody drug, and more.
☆ Novartis generated $40 billion in innovative medicine sales, says CEO
  + stars: | 2023-01-10 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis generated $40 billion in innovative medicine sales, says CEOCNBC's Meg Tirrell sits down with Dr. Vas Narasimhan, CEO of Novartis International on drug development and future of the company.
☆ CMS limiting coverage of Alzheimer's drug not a 'fixed' policy, says FDA's Robert Califf
  + stars: | 2023-01-10 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCMS limiting coverage of Alzheimer's drug not a 'fixed' policy, says FDA's Robert CaliffCNBC's Meg Tirrell and Dr. Robert Califf, FDA commissioner, joins 'Power Lunch' to discuss Biogen's Alzheimer's drug and the health care sector.
☆ Watch CNBC's full interview with Moderna CEO Stephane Bancel
  + stars: | 2023-01-09 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Moderna CEO Stephane BancelCNBC’s Meg Tirrell joins ‘Closing Bell’ to talk with Moderna CEO Stephane Bancel about the company’s Covid vaccine sales in 2022 and his projections for 2023.
☆ Pfizer CEO: 2022 was one of the most successful years in our corporate history
  + stars: | 2023-01-09 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO: 2022 was one of the most successful years in our corporate historyCNBC's Meg Tirrell sits down with Pfizer CEO Albert Bourla to discuss the Covid crisis and Pfizer's future in producing 19 new products in the next 18 months.
☆ We are in discussion with the Chinese government over the Covid vaccine, says Moderna CEO
  + stars: | 2023-01-09 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe are in discussion with the Chinese government over the Covid vaccine, says Moderna CEOCNBC’s Meg Tirrell joins ‘Closing Bell’ to talk with Moderna CEO Stephane Bancel about the company’s Covid vaccine sales in 2022 and his projections for 2023.
☆ FDA approves Biogen's Alzheimer's drug
  + stars: | 2023-01-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA approves Biogen's Alzheimer's drugCNBC's Meg Tirrell reports on Biogen and the company receiving FDA approval for an Alzheimer's treatment.
☆ Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments
  + stars: | 2023-01-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAlzheimer's drug decision day: FDA to decide on Biogen and Eisai treatmentsCNBC's Meg Tirrell joins 'Squawk Box' to discuss the big day ahead for Alzheimer's medicine.
☆ CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval
  + stars: | 2023-01-06 | by ( Melissa Lee | ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approvalCNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's Alzheimer's drug receiving approval from the FDA today. With CNBC's Tyler Mathisen and the Fast Money traders, Tim Seymour, Bonawyn Eison, Steve Grasso and Jeff Mills.
☆ New Covid variant XBB.1.5 is the most transmissible subvariant that has been detected yet, says WHO
  + stars: | 2023-01-04 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew Covid variant XBB.1.5 is the most transmissible subvariant that has been detected yet, says WHOCNBC's Meg Tirrell joins 'The Exchange' to repot on China's covid cases, the omicron variant currently spreading and what it could mean for both China and global markets.
<< prev 3 next >>
Total: 12